Oscar Arrieta1, Andrés F Cardona2, Claudio Martín3, Luis Más-López4, Luis Corrales-Rodríguez5, Guillermo Bramuglia6, Omar Castillo-Fernandez7, Matthew Meyerson8, Eduardo Amieva-Rivera9, Alma Delia Campos-Parra9, Hernán Carranza2, Juan Carlos Gómez de la Torre4, Yanina Powazniak10, Fernando Aldaco-Sarvide11, Carlos Vargas2, Mariana Trigo10, Manuel Magallanes-Maciel11, Jorge Otero2, Roberto Sánchez-Reyes9, Mauricio Cuello12. 1. Thoracic Oncology Clinic and Experimental Oncology Laboratory, Instituto Nacional de Cancerologia de México, México D.F., México. Electronic address: ogar@unam.mx. 2. Clinical and Translational Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia. 3. Department of Oncology, Alexander Fleming Institute, Buenos Aires, Argentina; Oncología Médica, Hospital San Juan de Dios, San José, Costa Rica. 4. Department of Clinical Oncology, Instituto de Enfermedades Neoplásicas, Perú. 5. Oncología Médica, Hospital San Juan de Dios, San José, Costa Rica. 6. Cátedra de Farmacología, Facultad de Farmacia y Bioquimica, Universidad de Buenos, Fundación Investigar, Buenos Aires, Argentina; Oncología Médica, Hospital San Juan de Dios, San José, Costa Rica. 7. Instituto Oncológico Nacional, Ancón, Panamá. 8. Broad Institute of Harvard, Massachusetts Institute of Technology, Cambridge, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 9. Thoracic Oncology Clinic and Experimental Oncology Laboratory, Instituto Nacional de Cancerologia de México, México D.F., México. 10. Cátedra de Farmacología, Facultad de Farmacia y Bioquimica, Universidad de Buenos, Fundación Investigar, Buenos Aires, Argentina. 11. Centro Médico Nacional 20 de Noviembre de México, ISSSTE, México D.F., México. 12. Departament of Medicine, Hospital de Clínicas UdelaR, Montevideo, Uruguay; Clínica Del Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires.
Abstract
INTRODUCTION: Previously, we reported the frequency of epidermal growth factor receptor (EGFR) and KRAS mutations in nonsmall-cell lung cancer (NSCLC) patients in Latin America. The EGFR mutation frequency was found between Asian (40%) and Caucasian (15%) populations. Here, we report the updated distribution of NSCLC mutations. METHODS: A total of 5738 samples from NSCLC patients from Argentina (1713), Mexico (1417), Colombia (1939), Peru (393), Panama (174), and Costa Rica (102) were genotyped for EGFR and KRAS. RESULTS: The median patient age was 62.2 ± 12.3 years; 53.5% were women, 46.7% had a history of smoking, and 95.2% had adenocarcinoma histology. The frequency of EGFR mutations was 26.0% (95% confidence interval [CI], 24.9-27.1; Argentina, 14.4% [12.8-15.6]; México, 34.3% [31.9-36.7]; Colombia, 24.7% [22.8-26.6]; Peru, 51.1% [46.2-55.9]; Panamá, 27.3 [20.7-33.9]; and Costa Rica, 31.4% [22.4-40.4]). The frequency of KRAS mutations was 14.0% (9.1-18.9). In patients with adenocarcinoma, EGFR mutations were independently associated with gender (30.7% females vs. 18.4% males; p < 0.001), nonsmoker status (27.4% vs. 17.1%, p < 0.001), ethnicity (mestizo/indigenous, 35.3% vs. Caucasian, 13.7%, p < 0.001), and the absence of KRAS mutation (38.1% vs. 4.7%; p < 0.001). The overall response rate to EGFR tyrosine kinase inhibitors was 60.6% (95% CI, 52-69), with a median progression-free survival and overall survival of 15.9 (95% CI, 12.420.6) and 32 months (95% CI, 26.5-37.6), respectively. CONCLUSION: Our findings support the genetic heterogeneity of NSCLC in Latin America, confirming that the frequency of EGFR mutations is intermediate between that observed in the Asian and Caucasian populations.
INTRODUCTION: Previously, we reported the frequency of epidermal growth factor receptor (EGFR) and KRAS mutations in nonsmall-cell lung cancer (NSCLC) patients in Latin America. The EGFR mutation frequency was found between Asian (40%) and Caucasian (15%) populations. Here, we report the updated distribution of NSCLC mutations. METHODS: A total of 5738 samples from NSCLCpatients from Argentina (1713), Mexico (1417), Colombia (1939), Peru (393), Panama (174), and Costa Rica (102) were genotyped for EGFR and KRAS. RESULTS: The median patient age was 62.2 ± 12.3 years; 53.5% were women, 46.7% had a history of smoking, and 95.2% had adenocarcinoma histology. The frequency of EGFR mutations was 26.0% (95% confidence interval [CI], 24.9-27.1; Argentina, 14.4% [12.8-15.6]; México, 34.3% [31.9-36.7]; Colombia, 24.7% [22.8-26.6]; Peru, 51.1% [46.2-55.9]; Panamá, 27.3 [20.7-33.9]; and Costa Rica, 31.4% [22.4-40.4]). The frequency of KRAS mutations was 14.0% (9.1-18.9). In patients with adenocarcinoma, EGFR mutations were independently associated with gender (30.7% females vs. 18.4% males; p < 0.001), nonsmoker status (27.4% vs. 17.1%, p < 0.001), ethnicity (mestizo/indigenous, 35.3% vs. Caucasian, 13.7%, p < 0.001), and the absence of KRAS mutation (38.1% vs. 4.7%; p < 0.001). The overall response rate to EGFR tyrosine kinase inhibitors was 60.6% (95% CI, 52-69), with a median progression-free survival and overall survival of 15.9 (95% CI, 12.420.6) and 32 months (95% CI, 26.5-37.6), respectively. CONCLUSION: Our findings support the genetic heterogeneity of NSCLC in Latin America, confirming that the frequency of EGFR mutations is intermediate between that observed in the Asian and Caucasian populations.
Authors: Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó Journal: Pharmacogenomics Date: 2016-09-16 Impact factor: 2.533
Authors: Nicholas T Gimbrone; Bhaswati Sarcar; Edna R Gordian; Jason I Rivera; Christian Lopez; Sean J Yoder; Jamie K Teer; Eric A Welsh; Alberto A Chiappori; Matthew B Schabath; Gary W Reuther; Julie Dutil; Miosotis Garcia; Ronald Ventosilla-Villanueva; Luis Vera-Valdivia; Alejandro Yabar-Berrocal; Rodrigo Motta-Guerrero; Pedro G Santiago-Cardona; Teresita Muñoz-Antonia; W Douglas Cress Journal: J Thorac Oncol Date: 2017-09-11 Impact factor: 15.609
Authors: Oscar Arrieta; Feliciano Barrón; Laura Alejandra Ramírez-Tirado; Zyanya Lucia Zatarain-Barrón; Andrés F Cardona; Diego Díaz-García; Masao Yamamoto Ramos; Beatriz Mota-Vega; Amir Carmona; Marco Polo Peralta Álvarez; Yolanda Bautista; Fernando Aldaco; Raquel Gerson; Christian Rolfo; Rafael Rosell Journal: JAMA Oncol Date: 2020-06-01 Impact factor: 31.777
Authors: Oscar Arrieta; Pablo Anaya; Vicente Morales-Oyarvide; Laura Alejandra Ramírez-Tirado; Ana C Polanco Journal: Eur J Health Econ Date: 2015-09-04